All In Biotech

Drug Trial Radar · NCT04127578

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jan 3, 2020

Primary completion

Aug 31, 2031

Study completion Aug 31, 2031

Sponsor

Lead sponsor
Prevail TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Oct 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and clinical efficacy measures. Patients will continue to be followed for an additional 4 years to continue to monitor safety as well as selected biomarker and efficacy measures.

Conditions

  • Parkinson Disease

Interventions

  • LY3884961Biological

    Participants will receive a single dose of LY3884961, administered intra-cisterna magna

  • MethylprednisoloneDrug

    6 IV pulses administered as concomitant medication over 3 months

  • SirolimusDrug

    Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: 5 years
  2. Incidence of procedure or treatment-emergent AEs measured by brain MRI, spine MRI and nerve conduction study (NCS)Time frame: 5 years
  3. Treatment emergent immunogenicity of AAV9 in bloodTime frame: Thru month 24
  4. Change from baseline in immunogenicity of AAV9 in bloodTime frame: Baseline and Month 24
  5. Treatment emergent immunogenicity of GCase in bloodTime frame: Thru Month 24
  6. Change from baseline in immunogenicity of GCase in bloodTime frame: Baseline and Months 24
  7. Treatment emergent immunogenicity of Nfl in bloodTime frame: Thru Month 24
  8. Change from baseline in immunogenicity of Nfl in bloodTime frame: Baseline and Month 24
  9. Treatment emergent immunogenicity of AAV9 in CSFTime frame: Thru Month 24
  10. Change in immunogenicity of AAV9 in CSFTime frame: Baseline and Month 12
  11. Treatment emergent immunogenicity of GCase in CSFTime frame: Thru Month 24
  12. Change in immunogenicity of GCase in CSFTime frame: Baseline, and Months 12

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic, 13400 E. Shea Boulevard

    Scottsdale, Arizona

  • Esperanza Clinical, 25220 Hancock Avenue

    Murrieta, California

  • Rocky Mountain Clinical Research - CenExel - PPDS, 701 East Hampden Avenue Suite 510

    Englewood, Colorado

  • K2 Medical Research, 101 Southhall Lane, Suite 150

    Maitland, Florida

  • PPD, 100 West Gore Street, Suite 202

    Orlando, Florida

  • Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor

    Chicago, Illinois

  • Mayo Clinic, 200 First Street SW

    Rochester, Minnesota

  • Mount Sinai Beth Israel, 10 Union Square East, Suite 5H

    New York, New York

  • Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street

    New York, New York

  • Hospital of the University of Pennsylvania, 330 S. 9th Street

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center, 1500 21st Avenue South Suite 2600

    Nashville, Tennessee

  • Shaare Zedek Medical Center, 12 Shmuel Biet Street

    Jerusalem, Israel

  • Hadassah Medical Center, Hadassah Ein Kerem, Dept. of Neurology, P.O. Box 12000

    Jerusalem, Israel

  • Sheba Medical Center, Tel Hashomer

    Ramat Gan, Israel

  • Tel Aviv Sourasky Medical Center, 6 Weizmann St.

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.